rosiglitazone has been researched along with Recrudescence in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, M; Hu, J; Li, M; Yao, L | 1 |
| Liu, J; Wang, LN | 1 |
| GuiLian, Z; HaiQin, W; Hong, S; HuQing, W; Li, Y; Ning, B; Ru, Z; ShuQin, Z; Xin, Y; YongNan, L | 1 |
| Fisher, M | 1 |
2 review(s) available for rosiglitazone and Recrudescence
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.
Topics: Cardiovascular Diseases; Carotid Artery Diseases; Humans; Hypoglycemic Agents; Insulin Resistance; Ischemic Attack, Transient; Myocardial Infarction; Pioglitazone; PPAR gamma; Proteasome Endopeptidase Complex; Randomized Controlled Trials as Topic; Recurrence; Rosiglitazone; Secondary Prevention; Stroke; Thiazolidinediones; Ubiquitin | 2017 |
Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
Topics: Atherosclerosis; Biomarkers; Blood Glucose; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Pioglitazone; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Rosiglitazone; Stents; Thiazolidinediones; Tunica Intima; Tunica Media; Vascular Resistance | 2009 |
2 other study(ies) available for rosiglitazone and Recrudescence
| Article | Year |
|---|---|
Decreased ANGPTL4 impairs endometrial angiogenesis during peri-implantation period in patients with recurrent implantation failure.
Topics: Adult; Angiopoietin-Like Protein 4; Cell Line; Decidua; Electric Impedance; Embryo Implantation; Embryo Loss; Embryo Transfer; Endometrium; Female; Fertilization in Vitro; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Physiologic; PPAR gamma; Pregnancy; Recurrence; Rosiglitazone; Sperm Injections, Intracytoplasmic; Stromal Cells; Uterine Artery; Young Adult | 2020 |
The PPARĪ³ agonist rosiglitazone prevents neuronal loss and attenuates development of spontaneous recurrent seizures through BDNF/TrkB signaling following pilocarpine-induced status epilepticus.
Topics: Animals; Anticonvulsants; Brain-Derived Neurotrophic Factor; Electroencephalography; Enzyme-Linked Immunosorbent Assay; Hippocampus; Male; Neurons; Pilocarpine; PPAR gamma; Rats; Rats, Sprague-Dawley; Receptor, trkB; Recurrence; Rosiglitazone; Signal Transduction; Status Epilepticus; Thiazolidinediones | 2013 |